Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 157Brain Neoplasms 98Glioma 69Gliosarcoma 43Astrocytoma 30Carcinoma, Non-Small-Cell Lung 19Recurrence 18Oligodendroglioma 18Central Nervous System Neoplasms 16Neoplasms 14Meningeal Carcinomatosis 10Ependymoma 10Meningioma 7Neurofibromatosis 2 6Neuroblastoma 6Melanoma 6Diffuse Intrinsic Pontine Glioma 6Neuroma, Acoustic 5Medulloblastoma 5Lung Neoplasms 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neurologic Manifestations 4Colorectal Neoplasms 4Breast Neoplasms 4Spinal Cord Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3

Interventions

vandetanib 2Bevacizumab 2Anthropogenic Effects 2enzastaurin 1carotuximab 1Temozolomide 1Tamoxifen 1Steroids 1Irinotecan 1Carboplatin 1Bortezomib 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease Progression × Bevacizumab × CNS × Clear all
NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown
146 enrolled
CNS

Glioblastoma, Recurrence, Disease Progression

NCT00393094 2012-07-13

Bevacizumab and Irinotecan to Treat Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
31 enrolled 12 charts
CNS

Brain Neoplasms, Glioma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡